Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy by Tatsushi Kawada, Satoshi Katayama, Takafumi Yanagisawa, Keiichiro Mori, Wataru Fukuokaya, Kazumasa Komura, Takuya Tsujino, Ryoichi Maenosono, Kiyoshi Takahara, Takuhisa Nukaya, Lan Inoki, Shingo Toyoda, Takeshi Hashimoto, Yosuke Hirasawa, Kohei Edamura, Tomoko Kobayashi, Kensuke Bekku, Shingo Nishimura, Takehiro Iwata, Takuya Sadahira, Yusuke Tominaga, Tomoaki Yamanoi, Kasumi Yoshinaga, Kazuma Tsuboi, Yasuyuki Kobayashi, Atsushi Takamoto, Kyohei Kurose, Takahiro Kimura, Haruhito Azuma, Ryoichi Shiroki, Kazutoshi Fujita, Yoshio Ohno, Motoo Araki, On behalf of JK-FOOT study group

Get full text